Covered recipient · General Payments record
MICHAEL JAMES DOWNING
Allopathic & Osteopathic Physicians Psychiatry & Neurology Psychiatry
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2019 · Entire year
$327.48
15 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2019 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $327.48 | 15 |
By paying entity
PY2019 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | $99.47 | 1 |
| Alkermes, Inc. | $60.29 | 4 |
| Indivior Inc. | $48.24 | 3 |
| Janssen Pharmaceuticals, Inc | $44.59 | 2 |
| Allergan Inc. | $31.67 | 2 |
| Neurocrine Biosciences, Inc. | $18.14 | 1 |
| JAZZ PHARMACEUTICALS INC. | $12.70 | 1 |
| Lundbeck LLC | $12.38 | 1 |
Page 1 of 1; records 1–15 of 15 matching records. This page contains 15 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
MICHAEL JAMES DOWNING
NPI 1639159346 · CMS profile ID 300554
Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Psychiatry
DALLAS, TX
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 1 of 1; records 1–15 of 15 matching records. This page contains 15 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1639159346?year=2019&recipient=provider#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- MICHAEL JAMES DOWNING, NPI 1639159346, CMS profile ID 300554. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–15 of 15 matching records. This page contains 15 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1639159346?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- APA 7
- IndustryPayments. (2026). MICHAEL JAMES DOWNING, NPI 1639159346, CMS profile ID 300554. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–15 of 15 matching records. This page contains 15 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1639159346?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- Bluebook
- MICHAEL JAMES DOWNING, NPI 1639159346, CMS profile ID 300554, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–15 of 15 matching records. This page contains 15 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1639159346?year=2019&recipient=provider#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2019
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30
15 matching records · $327.48 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 1–15 of 15.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Alkermes, Inc. | $15.51 | 12/04/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 686585003 | CMS |
| Neurocrine Biosciences, Inc. | $18.14 | 11/19/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 693124787 | CMS |
| Indivior Inc. | $16.04 | 10/22/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 705775213 | CMS |
| Alkermes, Inc. | $12.14 | 09/25/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 686585005 | CMS |
| Alkermes, Inc. | $14.06 | 08/30/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 686585001 | CMS |
| Janssen Pharmaceuticals, Inc | $19.57 | 08/13/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658527621 | CMS |
| Indivior Inc. | $12.07 | 07/16/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 705775211 | CMS |
| JAZZ PHARMACEUTICALS INC. | $12.70 | 07/15/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 684174127 | CMS |
| Allergan Inc. | $17.52 | 07/11/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 670271099 | CMS |
| Indivior Inc. | $20.13 | 06/11/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 705775209 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $99.47 | 05/29/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 682109013 | CMS |
| Lundbeck LLC | $12.38 | 04/04/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 684293419 | CMS |
| Janssen Pharmaceuticals, Inc | $25.02 | 03/14/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658527615 | CMS |
| Alkermes, Inc. | $18.58 | 03/06/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 686584999 | CMS |
| Allergan Inc. | $14.15 | 01/24/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 670271096 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $914,450.61 | 88 |
| PY2024 | Recipient | $2,949.66 | 2 |
| PY2024 | Principal investigator | $1,362,460.91 | 98 |
| PY2023 | Recipient | $59,611.81 | 14 |
| PY2023 | Principal investigator | $997,596.68 | 181 |
| PY2022 | Principal investigator | $897,046.39 | 115 |
| PY2021 | Principal investigator | $714,455.57 | 113 |
| PY2020 | Principal investigator | $1,352,717.69 | 219 |
| PY2019 | Recipient | $157,177.13 | 20 |
| PY2019 | Principal investigator | $1,373,636.72 | 268 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2021
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
113 records in PY2021
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Allergan, Inc. | $400.00 | 12/31/2021 | Non-covered Recipient Entity FUTURESEARCH TRIALS | A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER | No dispute reported | 06/30/2026 | 789018817 |
| Principal investigator 1 | Allergan, Inc. | $1,228.00 | 12/31/2021 | Non-covered Recipient Entity FUTURESEARCH TRIALS | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE WHO HAVE PREVIOUSLY FAILED 2 | No dispute reported | 06/30/2026 | 789018819 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $46.69 | 12/31/2021 | Non-covered Recipient Entity FUTURESEARCH TRIALS OF DALLAS | A Phase III, Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Clinical Trial to Study the Efficacy and Safety of MK-8931 SCH 900931 in Subjects with Amnestic Mild Cognitive Impairment Due to Alzheimer s Disease Prodromal AD. | No dispute reported | 06/30/2026 | 848764343 |
| Principal investigator 1 | Supernus Pharmaceuticals, Inc. | $8,365.27 | 12/28/2021 | Non-covered Recipient Entity FUTURESEARCH TRIALS OF DALLAS LP | AN OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF SPN-812 IN ADULTS WITH ATTENTION- DEFICIT/HYPERACTIVITY DISORDER | No dispute reported | 06/30/2026 | 844990227 |
| Principal investigator 1 | Sage Therapeutics, Inc. | $2,054.52 | 12/22/2021 | Non-covered Recipient Entity FUTURESEARCH TRIALS OF DALLAS LP | A COMPARATIVE STUDY OF SAGE-217 PLUS SERTRALINE VERSUS PLACEBO PLUS SERTRALINE IN ADULTS WITH MAJOR DEPRESSIVE DISORDER | No dispute reported | 06/30/2026 | 837511411 |
| Principal investigator 1 | Biohaven Pharmaceuticals, Inc. | $13,258.00 | 12/21/2021 | Non-covered Recipient Entity FUTURESEARCH TRIALS OF DALLAS LP | A Phase 2/3 Randomized Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention | No dispute reported | 06/30/2026 | 851032063 |
| Principal investigator 1 | Eisai Inc. | $1,000.00 | 12/20/2021 | Non-covered Recipient Entity FUTURE SEARCH TRIALS OF NEUROLOGY | A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 836166641 |
| Principal investigator 1 | Eisai Inc. | $500.00 | 12/20/2021 | Non-covered Recipient Entity FUTURE SEARCH TRIALS OF NEUROLOGY | A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 836166643 |
| Principal investigator 1 | Eisai Inc. | $200.00 | 12/20/2021 | Non-covered Recipient Entity FUTURE SEARCH TRIALS OF NEUROLOGY | A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 836166645 |
| Principal investigator 1 | Purdue Pharma L.P. | $513.00 | 12/20/2021 | Non-covered Recipient Entity FUTURESEARCH TRIALS OF DALLAS LP | Real-world Evidence of Duration of Adhansia XR for treatment of ADHD (REDAX): An open-label pragmatic study to assess the real-world effectiveness of Adhansia XR in treatment of adult and adolescent patients with ADHD in the United States | No dispute reported | 06/30/2026 | 844882615 |
| Principal investigator 1 | Allergan, Inc. | $1,980.00 | 12/16/2021 | Non-covered Recipient Entity FUTURESEARCH TRIALS OF DALLAS | A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER | No dispute reported | 06/30/2026 | 789018813 |
| Principal investigator 1 | Allergan, Inc. | $6.85 | 12/16/2021 | Non-covered Recipient Entity FUTURESEARCH TRIALS OF DALLAS | A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER | No dispute reported | 06/30/2026 | 789018815 |
| Principal investigator 1 | Biohaven Pharmaceuticals, Inc. | $1,700.00 | 12/16/2021 | Non-covered Recipient Entity FUTURESEARCH TRIALS OF DALLAS LP | Phase 3 Multicenter Randomized Double-blindGroup Sequential Placebo-controlled Study to Assess Efficacy and Safety of Rimegepant or the Treatment of Migraine (With or Without Aura) in Children and Adolescents = 6 to <18 Years of Age | No dispute reported | 06/30/2026 | 851031473 |
| Principal investigator 1 | Sage Therapeutics, Inc. | $1,192.81 | 12/16/2021 | Non-covered Recipient Entity FUTURESEARCH TRIALS OF DALLAS LP | A COMPARATIVE STUDY OF SAGE-217 PLUS SERTRALINE VERSUS PLACEBO PLUS SERTRALINE IN ADULTS WITH MAJOR DEPRESSIVE DISORDER | No dispute reported | 06/30/2026 | 837511253 |
| Principal investigator 1 | Allergan, Inc. | $7,036.45 | 12/14/2021 | Non-covered Recipient Entity FUTURESEARCH TRIALS OF DALLAS | A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER | No dispute reported | 06/30/2026 | 789018809 |
| Principal investigator 1 | Allergan, Inc. | $2,000.00 | 12/14/2021 | Non-covered Recipient Entity FUTURESEARCH TRIALS OF DALLAS | A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER | No dispute reported | 06/30/2026 | 789018811 |
| Principal investigator 1 | Sage Therapeutics, Inc. | $3,121.56 | 12/09/2021 | Non-covered Recipient Entity FUTURESEARCH TRIALS OF DALLAS LP | A COMPARATIVE STUDY OF SAGE-217 PLUS SERTRALINE VERSUS PLACEBO PLUS SERTRALINE IN ADULTS WITH MAJOR DEPRESSIVE DISORDER | No dispute reported | 06/30/2026 | 837511191 |
| Principal investigator 1 | Biohaven Pharmaceuticals, Inc. | $3,230.00 | 12/06/2021 | Non-covered Recipient Entity FUTURESEARCH TRIALS OF DALLAS LP | BHV3500-301: Phase 3: Double-Blind Randomized Placebo Controlled Safety and Efficacy Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine | No dispute reported | 06/30/2026 | 851031037 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $779.30 | 12/01/2021 | Non-covered Recipient Entity Future Search Trials Dallas Clinic | BI 425809 Adjunctive Computerized Cognitive Training (CCT) | No dispute reported | 06/30/2026 | 828335325 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $217.06 | 12/01/2021 | Non-covered Recipient Entity Future Search Trials Dallas Clinic | BI 425809 Adjunctive Computerized Cognitive Training (CCT) | No dispute reported | 06/30/2026 | 828335327 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $623.44 | 12/01/2021 | Non-covered Recipient Entity Future Search Trials Dallas Clinic | BI 425809 Adjunctive Computerized Cognitive Training (CCT) | No dispute reported | 06/30/2026 | 828335329 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $623.44 | 12/01/2021 | Non-covered Recipient Entity Future Search Trials Dallas Clinic | BI 425809 Adjunctive Computerized Cognitive Training (CCT) | No dispute reported | 06/30/2026 | 828335331 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $623.44 | 12/01/2021 | Non-covered Recipient Entity Future Search Trials Dallas Clinic | BI 425809 Adjunctive Computerized Cognitive Training (CCT) | No dispute reported | 06/30/2026 | 828335333 |
| Principal investigator 1 | Purdue Pharma L.P. | $1,026.00 | 12/01/2021 | Non-covered Recipient Entity FUTURESEARCH TRIALS OF DALLAS LP | Real-world Evidence of Duration of Adhansia XR for treatment of ADHD (REDAX): An open-label pragmatic study to assess the real-world effectiveness of Adhansia XR in treatment of adult and adolescent patients with ADHD in the United States | No dispute reported | 06/30/2026 | 844882351 |
| Principal investigator 1 | Eli Lilly and Company | $195.16 | 11/24/2021 | Non-covered Recipient Entity FUTURE SEARCH TRIALS OF DALLAS LP | A PHASE 4, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF GALCANEZUMAB VERSUS RIMEGEPANT IN ADULT PARTICIPANTS WITH EPISODIC MIGRAINE | No dispute reported | 06/30/2026 | 819460353 |
| Principal investigator 1 | Allergan, Inc. | $1,700.00 | 11/22/2021 | Non-covered Recipient Entity FUTURESEARCH TRIALS OF DALLAS | A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER | No dispute reported | 06/30/2026 | 789018801 |
| Principal investigator 1 | Allergan, Inc. | $1,000.00 | 11/22/2021 | Non-covered Recipient Entity FUTURESEARCH TRIALS OF DALLAS | A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER | No dispute reported | 06/30/2026 | 789018803 |
| Principal investigator 1 | Allergan, Inc. | $1,000.00 | 11/22/2021 | Non-covered Recipient Entity FUTURESEARCH TRIALS OF DALLAS | A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER | No dispute reported | 06/30/2026 | 789018805 |
| Principal investigator 1 | Allergan, Inc. | $250.00 | 11/22/2021 | Non-covered Recipient Entity FUTURESEARCH TRIALS OF DALLAS | A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER | No dispute reported | 06/30/2026 | 789018807 |
| Principal investigator 1 | Allergan, Inc. | $1,700.00 | 11/15/2021 | Non-covered Recipient Entity FUTURESEARCH TRIALS OF DALLAS | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE WHO HAVE PREVIOUSLY FAILED 2 | No dispute reported | 06/30/2026 | 789018799 |
| Principal investigator 1 | Allergan, Inc. | $4,936.20 | 11/12/2021 | Non-covered Recipient Entity FUTURESEARCH TRIALS OF DALLAS | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ORAL UBROGEPANT IN THE TREATMENT OF MIGRAINE WHEN ADMINSTERED DURING THE PREMONITORY PHASE | No dispute reported | 06/30/2026 | 789018797 |
| Principal investigator 1 | Sage Therapeutics, Inc. | $1,530.00 | 11/10/2021 | Non-covered Recipient Entity FUTURESEARCH TRIALS OF DALLAS LP | A COMPARATIVE STUDY OF SAGE-217 PLUS SERTRALINE VERSUS PLACEBO PLUS SERTRALINE IN ADULTS WITH MAJOR DEPRESSIVE DISORDER | No dispute reported | 06/30/2026 | 837510645 |
| Principal investigator 1 | Sage Therapeutics, Inc. | $22,110.27 | 11/10/2021 | Non-covered Recipient Entity FUTURESEARCH TRIALS OF DALLAS LP | A COMPARATIVE STUDY OF SAGE-217 PLUS SERTRALINE VERSUS PLACEBO PLUS SERTRALINE IN ADULTS WITH MAJOR DEPRESSIVE DISORDER | No dispute reported | 06/30/2026 | 837510647 |
| Principal investigator 1 | Otsuka Pharmaceutical Development & Commercialization, Inc. | $6,248.00 | 10/28/2021 | Non-covered Recipient Entity FUTURESEARCH TRIALS OF DALLAS LP | A MULTI-CENTER, RANDOMIZED, CONTROLLED TRIAL TO EVALUATE THE EFFECTIVENESS OF A DIGITAL THERAPEUTIC (CT-152) AS ADJUNCTIVE THERAPY IN ADULT SUBJECTS DIAGNOSED WITH MAJOR DEPRESSIVE DISORDER | No dispute reported | 06/30/2026 | 844175083 |
| Principal investigator 1 | Purdue Pharma L.P. | $1,105.80 | 10/25/2021 | Non-covered Recipient Entity FUTURESEARCH TRIALS OF DALLAS LP | Real-world Evidence of Duration of Adhansia XR for treatment of ADHD (REDAX): An open-label pragmatic study to assess the real-world effectiveness of Adhansia XR in treatment of adult and adolescent patients with ADHD in the United States | No dispute reported | 06/30/2026 | 844882187 |
| Principal investigator 1 | Biohaven Pharmaceuticals, Inc. | $13,741.75 | 10/22/2021 | Non-covered Recipient Entity FUTURESEARCH TRIALS OF DALLAS LP | BHV3500-301: Phase 3: Double-Blind Randomized Placebo Controlled Safety and Efficacy Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine | No dispute reported | 06/30/2026 | 851028517 |
| Principal investigator 1 | Eisai Inc. | $3,170.00 | 10/15/2021 | Non-covered Recipient Entity FUTURE SEARCH TRIALS OF NEUROLOGY | A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 836166639 |
| Principal investigator 1 | Allergan, Inc. | $9,044.95 | 10/13/2021 | Non-covered Recipient Entity FUTURESEARCH TRIALS OF DALLAS | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ORAL UBROGEPANT IN THE TREATMENT OF MIGRAINE WHEN ADMINSTERED DURING THE PREMONITORY PHASE | No dispute reported | 06/30/2026 | 789018795 |
| Principal investigator 1 | Biohaven Pharmaceuticals, Inc. | $5,750.00 | 10/07/2021 | Non-covered Recipient Entity FUTURESEARCH TRIALS OF DALLAS LP | Phase 3 Multicenter Randomized Double-blindGroup Sequential Placebo-controlled Study to Assess Efficacy and Safety of Rimegepant or the Treatment of Migraine (With or Without Aura) in Children and Adolescents = 6 to <18 Years of Age | No dispute reported | 06/30/2026 | 851027929 |
| Principal investigator 1 | Purdue Pharma L.P. | $1,105.80 | 10/04/2021 | Non-covered Recipient Entity FUTURESEARCH TRIALS OF DALLAS LP | Real-world Evidence of Duration of Adhansia XR for treatment of ADHD (REDAX): An open-label pragmatic study to assess the real-world effectiveness of Adhansia XR in treatment of adult and adolescent patients with ADHD in the United States | No dispute reported | 06/30/2026 | 844882077 |
| Principal investigator 1 | Biohaven Pharmaceuticals, Inc. | $14,490.35 | 09/27/2021 | Non-covered Recipient Entity FUTURESEARCH TRIALS OF DALLAS LP | BHV3500-301: Phase 3: Double-Blind Randomized Placebo Controlled Safety and Efficacy Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine | No dispute reported | 06/30/2026 | 851027583 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,792.00 | 09/27/2021 | Non-covered Recipient Entity FUTURESEARCH TRIALS OF DALLAS LP | An Open label Long term Extension Safety Study of Intranasal Esketamine in Treatment resistant Depression | No dispute reported | 06/30/2026 | 787664309 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,075.45 | 09/27/2021 | Non-covered Recipient Entity FUTURESEARCH TRIALS OF DALLAS LP | An Open label Long term Extension Safety Study of Intranasal Esketamine in Treatment resistant Depression | No dispute reported | 06/30/2026 | 787664325 |
| Principal investigator 1 | Sage Therapeutics, Inc. | $3,568.50 | 09/22/2021 | Non-covered Recipient Entity FUTURESEARCH TRIALS OF DALLAS LP | A PHASE 3, OPEN-LABEL, 1-YEAR STUDY OF THE SAFETY, TOLERABILITY, AND NEED FOR RE-TREATMENT WITH SAGE-217 IN ADULT SUBJECTS WITH MAJOR DEPRESSIVE DISORDER | No dispute reported | 06/30/2026 | 837509995 |
| Principal investigator 1 | Allergan, Inc. | $15,676.90 | 09/14/2021 | Non-covered Recipient Entity FUTURESEARCH TRIALS OF DALLAS | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ORAL UBROGEPANT IN THE TREATMENT OF MIGRAINE WHEN ADMINSTERED DURING THE PREMONITORY PHASE | No dispute reported | 06/30/2026 | 789018793 |
| Principal investigator 1 | Allergan, Inc. | $10,000.00 | 09/01/2021 | Non-covered Recipient Entity FUTURESEARCH TRIALS OF DALLAS | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE WHO HAVE PREVIOUSLY FAILED 2 | No dispute reported | 06/30/2026 | 789018789 |
| Principal investigator 1 | Allergan, Inc. | $500.00 | 09/01/2021 | Non-covered Recipient Entity FUTURESEARCH TRIALS OF DALLAS | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE WHO HAVE PREVIOUSLY FAILED 2 | No dispute reported | 06/30/2026 | 789018791 |
| Principal investigator 1 | Purdue Pharma L.P. | $8,624.10 | 09/01/2021 | Non-covered Recipient Entity FUTURESEARCH TRIALS OF DALLAS LP | Real-world Evidence of Duration of Adhansia XR for treatment of ADHD (REDAX): An open-label pragmatic study to assess the real-world effectiveness of Adhansia XR in treatment of adult and adolescent patients with ADHD in the United States | No dispute reported | 06/30/2026 | 844881921 |
| Principal investigator 1 | Biohaven Pharmaceuticals, Inc. | $11,424.70 | 08/31/2021 | Non-covered Recipient Entity FUTURESEARCH TRIALS OF DALLAS LP | BHV3500-301: Phase 3: Double-Blind Randomized Placebo Controlled Safety and Efficacy Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine | No dispute reported | 06/30/2026 | 851027099 |
| Principal investigator 1 | Allergan, Inc. | $13,826.30 | 08/13/2021 | Non-covered Recipient Entity FUTURESEARCH TRIALS OF DALLAS | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ORAL UBROGEPANT IN THE TREATMENT OF MIGRAINE WHEN ADMINSTERED DURING THE PREMONITORY PHASE | No dispute reported | 06/30/2026 | 789018785 |
| Principal investigator 1 | Allergan, Inc. | $1,167.55 | 08/13/2021 | Non-covered Recipient Entity FUTURESEARCH TRIALS OF DALLAS | A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER | No dispute reported | 06/30/2026 | 789018787 |
| Principal investigator 1 | Sage Therapeutics, Inc. | $4,063.41 | 08/11/2021 | Non-covered Recipient Entity FUTURESEARCH TRIALS OF DALLAS LP | A PHASE 3, OPEN-LABEL, 1-YEAR STUDY OF THE SAFETY, TOLERABILITY, AND NEED FOR RE-TREATMENT WITH SAGE-217 IN ADULT SUBJECTS WITH MAJOR DEPRESSIVE DISORDER | No dispute reported | 06/30/2026 | 837509415 |
| Principal investigator 1 | Janssen Research & Development, LLC | $10.99 | 08/09/2021 | Non-covered Recipient Entity FUTURESEARCH TRIALS OF DALLAS LP | An Open label Long term Extension Safety Study of Intranasal Esketamine in Treatment resistant Depression | No dispute reported | 06/30/2026 | 787664239 |
| Principal investigator 1 | Janssen Research & Development, LLC | $15,805.00 | 08/09/2021 | Non-covered Recipient Entity FUTURESEARCH TRIALS OF DALLAS LP | An Open label Long term Extension Safety Study of Intranasal Esketamine in Treatment resistant Depression | No dispute reported | 06/30/2026 | 787664257 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,612.00 | 08/09/2021 | Non-covered Recipient Entity FUTURESEARCH TRIALS OF DALLAS LP | An Open label Long term Extension Safety Study of Intranasal Esketamine in Treatment resistant Depression | No dispute reported | 06/30/2026 | 787664275 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,611.00 | 08/09/2021 | Non-covered Recipient Entity FUTURESEARCH TRIALS OF DALLAS LP | An Open label Long term Extension Safety Study of Intranasal Esketamine in Treatment resistant Depression | No dispute reported | 06/30/2026 | 787664291 |
| Principal investigator 1 | Purdue Pharma L.P. | $3,896.90 | 08/05/2021 | Non-covered Recipient Entity FUTURESEARCH TRIALS OF DALLAS LP | Real-world Evidence of Duration of Adhansia XR for treatment of ADHD (REDAX): An open-label pragmatic study to assess the real-world effectiveness of Adhansia XR in treatment of adult and adolescent patients with ADHD in the United States | No dispute reported | 06/30/2026 | 844881735 |
| Principal investigator 1 | Purdue Pharma L.P. | $5,529.00 | 07/27/2021 | Non-covered Recipient Entity FUTURESEARCH TRIALS OF DALLAS LP | Real-world Evidence of Duration of Adhansia XR for treatment of ADHD (REDAX): An open-label pragmatic study to assess the real-world effectiveness of Adhansia XR in treatment of adult and adolescent patients with ADHD in the United States | No dispute reported | 06/30/2026 | 844881697 |
| Principal investigator 1 | Biohaven Pharmaceuticals, Inc. | $15,177.20 | 07/26/2021 | Non-covered Recipient Entity FUTURESEARCH TRIALS OF DALLAS LP | BHV3500-301: Phase 3: Double-Blind Randomized Placebo Controlled Safety and Efficacy Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine | No dispute reported | 06/30/2026 | 851026347 |
| Principal investigator 1 | Sage Therapeutics, Inc. | $4,063.41 | 07/14/2021 | Non-covered Recipient Entity FUTURESEARCH TRIALS OF DALLAS LP | A PHASE 3, OPEN-LABEL, 1-YEAR STUDY OF THE SAFETY, TOLERABILITY, AND NEED FOR RE-TREATMENT WITH SAGE-217 IN ADULT SUBJECTS WITH MAJOR DEPRESSIVE DISORDER | No dispute reported | 06/30/2026 | 837509159 |
| Principal investigator 1 | Allergan, Inc. | $6,323.20 | 07/13/2021 | Non-covered Recipient Entity FUTURESEARCH TRIALS OF DALLAS | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ORAL UBROGEPANT IN THE TREATMENT OF MIGRAINE WHEN ADMINSTERED DURING THE PREMONITORY PHASE | No dispute reported | 06/30/2026 | 789018781 |
| Principal investigator 1 | Allergan, Inc. | $3,443.75 | 07/13/2021 | Non-covered Recipient Entity FUTURESEARCH TRIALS OF DALLAS | A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER | No dispute reported | 06/30/2026 | 789018783 |
| Principal investigator 1 | Biohaven Pharmaceuticals, Inc. | $837.50 | 07/08/2021 | Non-covered Recipient Entity FUTURESEARCH TRIALS OF DALLAS LP | A Phase 2/3 Randomized Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention | No dispute reported | 06/30/2026 | 851025827 |
| Principal investigator 1 | Biohaven Pharmaceuticals, Inc. | $2,934.00 | 07/08/2021 | Non-covered Recipient Entity FUTURESEARCH TRIALS OF DALLAS LP | A Phase 2/3 Randomized Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention | No dispute reported | 06/30/2026 | 851025829 |
| Principal investigator 1 | Biohaven Pharmaceuticals, Inc. | $5,493.40 | 07/08/2021 | Non-covered Recipient Entity FUTURESEARCH TRIALS OF DALLAS LP | A Phase 2/3 Randomized Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention | No dispute reported | 06/30/2026 | 851025965 |
| Principal investigator 1 | Biohaven Pharmaceuticals, Inc. | $1,000.00 | 07/08/2021 | Non-covered Recipient Entity FUTURESEARCH TRIALS OF DALLAS LP | A Phase 2/3 Randomized Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention | No dispute reported | 06/30/2026 | 851026019 |
| Principal investigator 1 | Biohaven Pharmaceuticals, Inc. | $600.00 | 07/08/2021 | Non-covered Recipient Entity FUTURESEARCH TRIALS OF DALLAS LP | A Phase 2/3 Randomized Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention | No dispute reported | 06/30/2026 | 851026021 |
| Principal investigator 1 | Biohaven Pharmaceuticals, Inc. | $3,000.00 | 07/08/2021 | Non-covered Recipient Entity FUTURESEARCH TRIALS OF DALLAS LP | A Phase 2/3 Randomized Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention | No dispute reported | 06/30/2026 | 851026023 |
| Principal investigator 1 | Biohaven Pharmaceuticals, Inc. | $6,041.05 | 06/29/2021 | Non-covered Recipient Entity FUTURESEARCH TRIALS OF DALLAS LP | BHV3500-301: Phase 3: Double-Blind Randomized Placebo Controlled Safety and Efficacy Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine | No dispute reported | 06/30/2026 | 851025421 |
| Principal investigator 1 | Biohaven Pharmaceuticals, Inc. | $12,592.25 | 06/29/2021 | Non-covered Recipient Entity FUTURESEARCH TRIALS OF DALLAS LP | BHV3500-301: Phase 3: Double-Blind Randomized Placebo Controlled Safety and Efficacy Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine | No dispute reported | 06/30/2026 | 851025423 |
| Principal investigator 1 | Biohaven Pharmaceuticals, Inc. | $20,444.00 | 06/29/2021 | Non-covered Recipient Entity FUTURESEARCH TRIALS OF DALLAS LP | BHV3500-301: Phase 3: Double-Blind Randomized Placebo Controlled Safety and Efficacy Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine | No dispute reported | 06/30/2026 | 851025425 |
| Principal investigator 1 | Biohaven Pharmaceuticals, Inc. | $1,000.00 | 06/17/2021 | Non-covered Recipient Entity FUTURESEARCH TRIALS OF DALLAS LP | A Phase 2/3 Randomized Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention | No dispute reported | 06/30/2026 | 851025263 |
| Principal investigator 1 | Biohaven Pharmaceuticals, Inc. | $3,250.00 | 06/17/2021 | Non-covered Recipient Entity FUTURESEARCH TRIALS OF DALLAS LP | A Phase 2/3 Randomized Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention | No dispute reported | 06/30/2026 | 851025265 |
| Principal investigator 1 | Sage Therapeutics, Inc. | $14,698.71 | 06/16/2021 | Non-covered Recipient Entity FUTURESEARCH TRIALS OF DALLAS LP | A PHASE 3, OPEN-LABEL, 1-YEAR STUDY OF THE SAFETY, TOLERABILITY, AND NEED FOR RE-TREATMENT WITH SAGE-217 IN ADULT SUBJECTS WITH MAJOR DEPRESSIVE DISORDER | No dispute reported | 06/30/2026 | 837508705 |
| Principal investigator 1 | Allergan, Inc. | $5,726.60 | 06/15/2021 | Non-covered Recipient Entity FUTURESEARCH TRIALS OF DALLAS | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ORAL UBROGEPANT IN THE TREATMENT OF MIGRAINE WHEN ADMINSTERED DURING THE PREMONITORY PHASE | No dispute reported | 06/30/2026 | 789018777 |
| Principal investigator 1 | Allergan, Inc. | $14,511.25 | 06/15/2021 | Non-covered Recipient Entity FUTURESEARCH TRIALS OF DALLAS | A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER | No dispute reported | 06/30/2026 | 789018779 |
| Principal investigator 1 | Allergan, Inc. | $237.95 | 06/08/2021 | Non-covered Recipient Entity FUTURESEARCH TRIALS OF DALLAS | A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER | No dispute reported | 06/30/2026 | 789018775 |
| Principal investigator 1 | Purdue Pharma L.P. | $10,562.10 | 06/02/2021 | Non-covered Recipient Entity FUTURESEARCH TRIALS OF DALLAS LP | Real-world Evidence of Duration of Adhansia XR for treatment of ADHD (REDAX): An open-label pragmatic study to assess the real-world effectiveness of Adhansia XR in treatment of adult and adolescent patients with ADHD in the United States | No dispute reported | 06/30/2026 | 844881493 |
| Principal investigator 1 | Sage Therapeutics, Inc. | $15,784.98 | 05/27/2021 | Non-covered Recipient Entity FUTURESEARCH TRIALS OF DALLAS LP | A COMPARATIVE STUDY OF SAGE-217 PLUS SERTRALINE VERSUS PLACEBO PLUS SERTRALINE IN ADULTS WITH MAJOR DEPRESSIVE DISORDER | No dispute reported | 06/30/2026 | 837508517 |
| Principal investigator 1 | Allergan, Inc. | $11,170.10 | 05/17/2021 | Non-covered Recipient Entity FUTURESEARCH TRIALS OF DALLAS | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ORAL UBROGEPANT IN THE TREATMENT OF MIGRAINE WHEN ADMINSTERED DURING THE PREMONITORY PHASE | No dispute reported | 06/30/2026 | 789018773 |
| Principal investigator 1 | Sage Therapeutics, Inc. | $3,433.95 | 05/12/2021 | Non-covered Recipient Entity FUTURESEARCH TRIALS OF DALLAS LP | A PHASE 3, OPEN-LABEL, 1-YEAR STUDY OF THE SAFETY, TOLERABILITY, AND NEED FOR RE-TREATMENT WITH SAGE-217 IN ADULT SUBJECTS WITH MAJOR DEPRESSIVE DISORDER | No dispute reported | 06/30/2026 | 837508273 |
| Principal investigator 1 | Supernus Pharmaceuticals, Inc. | $441.51 | 05/07/2021 | Non-covered Recipient Entity FUTURESEARCH TRIALS OF DALLAS LP | AN OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF SPN-812 IN ADULTS WITH ATTENTION- DEFICIT/HYPERACTIVITY DISORDER | No dispute reported | 06/30/2026 | 844987167 |
| Principal investigator 1 | Supernus Pharmaceuticals, Inc. | $19,139.00 | 04/27/2021 | Non-covered Recipient Entity FUTURESEARCH TRIALS OF DALLAS LP | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PARALLEL-GROUP FLEXIBLE-DOSE STUDY OF THE EFFICACY AND SAFETY OF SPN-812 IN ADULTS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD) | No dispute reported | 06/30/2026 | 844986833 |
| Principal investigator 1 | Sage Therapeutics, Inc. | $14,748.70 | 04/22/2021 | Non-covered Recipient Entity FUTURESEARCH TRIALS OF DALLAS LP | A COMPARATIVE STUDY OF SAGE-217 PLUS SERTRALINE VERSUS PLACEBO PLUS SERTRALINE IN ADULTS WITH MAJOR DEPRESSIVE DISORDER | No dispute reported | 06/30/2026 | 837507979 |
| Principal investigator 1 | Purdue Pharma L.P. | $4,322.50 | 04/20/2021 | Non-covered Recipient Entity FUTURESEARCH TRIALS OF DALLAS LP | Real-world Evidence of Duration of Adhansia XR for treatment of ADHD (REDAX): An open-label pragmatic study to assess the real-world effectiveness of Adhansia XR in treatment of adult and adolescent patients with ADHD in the United States | No dispute reported | 06/30/2026 | 844881375 |
| Principal investigator 1 | Sage Therapeutics, Inc. | $17,772.30 | 04/14/2021 | Non-covered Recipient Entity FUTURESEARCH TRIALS OF DALLAS LP | A PHASE 3, OPEN-LABEL, 1-YEAR STUDY OF THE SAFETY, TOLERABILITY, AND NEED FOR RE-TREATMENT WITH SAGE-217 IN ADULT SUBJECTS WITH MAJOR DEPRESSIVE DISORDER | No dispute reported | 06/30/2026 | 837507785 |
| Principal investigator 1 | Allergan, Inc. | $11,104.55 | 04/13/2021 | Non-covered Recipient Entity FUTURESEARCH TRIALS OF DALLAS | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ORAL UBROGEPANT IN THE TREATMENT OF MIGRAINE WHEN ADMINSTERED DURING THE PREMONITORY PHASE | No dispute reported | 06/30/2026 | 789018771 |
| Principal investigator 1 | ITI, Inc. | $100.00 | 04/08/2021 | Non-covered Recipient Entity FUTURESEARCH TRIALS OF DALLAS LP | An Open-Label, MultiCenter Trial to Assess the Safety and Effectiveness of ITI-007 in Patients with Schizophrenia | No dispute reported | 06/30/2026 | 830290167 |
| Principal investigator 1 | Supernus Pharmaceuticals, Inc. | $4,250.00 | 04/08/2021 | Non-covered Recipient Entity FUTURESEARCH TRIALS OF DALLAS LP | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PARALLEL-GROUP FLEXIBLE-DOSE STUDY OF THE EFFICACY AND SAFETY OF SPN-812 IN ADULTS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD) | No dispute reported | 06/30/2026 | 844986321 |
| Principal investigator 1 | Purdue Pharma L.P. | $9,206.45 | 04/06/2021 | Non-covered Recipient Entity FUTURESEARCH TRIALS OF DALLAS LP | Real-world Evidence of Duration of Adhansia XR for treatment of ADHD (REDAX): An open-label pragmatic study to assess the real-world effectiveness of Adhansia XR in treatment of adult and adolescent patients with ADHD in the United States | No dispute reported | 06/30/2026 | 844881335 |
| Principal investigator 1 | Eisai Inc. | $1,600.00 | 03/31/2021 | Non-covered Recipient Entity FUTURE SEARCH TRIALS OF NEUROLOGY | A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 836166637 |
| Principal investigator 1 | Supernus Pharmaceuticals, Inc. | $1,383.81 | 03/25/2021 | Non-covered Recipient Entity FUTURESEARCH TRIALS OF DALLAS LP | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PARALLEL-GROUP FLEXIBLE-DOSE STUDY OF THE EFFICACY AND SAFETY OF SPN-812 IN ADULTS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD) | No dispute reported | 06/30/2026 | 844985623 |
| Principal investigator 1 | Supernus Pharmaceuticals, Inc. | $1,959.33 | 03/25/2021 | Non-covered Recipient Entity FUTURESEARCH TRIALS OF DALLAS LP | AN OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF SPN-812 IN ADULTS WITH ATTENTION- DEFICIT/HYPERACTIVITY DISORDER | No dispute reported | 06/30/2026 | 844985693 |
| Principal investigator 1 | Sage Therapeutics, Inc. | $23,549.94 | 03/18/2021 | Non-covered Recipient Entity FUTURESEARCH TRIALS OF DALLAS LP | A COMPARATIVE STUDY OF SAGE-217 PLUS SERTRALINE VERSUS PLACEBO PLUS SERTRALINE IN ADULTS WITH MAJOR DEPRESSIVE DISORDER | No dispute reported | 06/30/2026 | 837507311 |
| Principal investigator 1 | Allergan, Inc. | $1,167.55 | 03/17/2021 | Non-covered Recipient Entity FUTURESEARCH TRIALS OF DALLAS | A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER | No dispute reported | 06/30/2026 | 789018769 |
| Principal investigator 1 | Sage Therapeutics, Inc. | $3,733.47 | 03/17/2021 | Non-covered Recipient Entity FUTURESEARCH TRIALS OF DALLAS LP | A PHASE 3, OPEN-LABEL, 1-YEAR STUDY OF THE SAFETY, TOLERABILITY, AND NEED FOR RE-TREATMENT WITH SAGE-217 IN ADULT SUBJECTS WITH MAJOR DEPRESSIVE DISORDER | No dispute reported | 06/30/2026 | 837507275 |
| Principal investigator 1 | ITI, Inc. | $25,982.50 | 03/16/2021 | Non-covered Recipient Entity FUTURESEARCH TRIALS OF DALLAS LP | An Open-Label, MultiCenter Trial to Assess the Safety and Effectiveness of ITI-007 in Patients with Schizophrenia | No dispute reported | 06/30/2026 | 830289943 |
| Principal investigator 1 | Allergan, Inc. | $18,280.85 | 03/15/2021 | Non-covered Recipient Entity FUTURESEARCH TRIALS OF DALLAS | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ORAL UBROGEPANT IN THE TREATMENT OF MIGRAINE WHEN ADMINSTERED DURING THE PREMONITORY PHASE | No dispute reported | 06/30/2026 | 789018767 |
| Principal investigator 1 | Sage Therapeutics, Inc. | $8,284.19 | 03/04/2021 | Non-covered Recipient Entity FUTURESEARCH TRIALS OF DALLAS LP | A COMPARATIVE STUDY OF SAGE-217 PLUS SERTRALINE VERSUS PLACEBO PLUS SERTRALINE IN ADULTS WITH MAJOR DEPRESSIVE DISORDER | No dispute reported | 06/30/2026 | 837507069 |
| Principal investigator 1 | Otsuka Pharmaceutical Development & Commercialization, Inc. | $11,465.55 | 02/24/2021 | Non-covered Recipient Entity FUTURESEARCH TRIALS OF DALLAS LP | AN OPEN-LABEL, 52-WEEK, MULTICENTER TRIAL EVALUATING THE LONG-TERM SAFETY AND TOLERABILITY OF CENTANAFADINE SUSTAINED-RELEASE TABLETS IN ADULTS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER | No dispute reported | 06/30/2026 | 844173415 |
| Principal investigator 1 | Purdue Pharma L.P. | $15,663.60 | 02/22/2021 | Non-covered Recipient Entity FUTURESEARCH TRIALS OF DALLAS LP | Real-world Evidence of Duration of Adhansia XR for treatment of ADHD (REDAX): An open-label pragmatic study to assess the real-world effectiveness of Adhansia XR in treatment of adult and adolescent patients with ADHD in the United States | No dispute reported | 06/30/2026 | 844881235 |
| Principal investigator 1 | Allergan, Inc. | $31,747.10 | 02/15/2021 | Non-covered Recipient Entity FUTURESEARCH TRIALS OF DALLAS | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ORAL UBROGEPANT IN THE TREATMENT OF MIGRAINE WHEN ADMINSTERED DURING THE PREMONITORY PHASE | No dispute reported | 06/30/2026 | 789018765 |
| Principal investigator 1 | Biohaven Pharmaceuticals, Inc. | $778.05 | 02/11/2021 | Non-covered Recipient Entity FUTURESEARCH TRIALS OF DALLAS LP | A Phase 2/3 Randomized Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention | No dispute reported | 06/30/2026 | 851021695 |
| Principal investigator 1 | Sage Therapeutics, Inc. | $26,415.03 | 02/11/2021 | Non-covered Recipient Entity FUTURESEARCH TRIALS OF DALLAS LP | A COMPARATIVE STUDY OF SAGE-217 PLUS SERTRALINE VERSUS PLACEBO PLUS SERTRALINE IN ADULTS WITH MAJOR DEPRESSIVE DISORDER | No dispute reported | 06/30/2026 | 837506645 |
| Principal investigator 1 | Sage Therapeutics, Inc. | $22,286.16 | 02/10/2021 | Non-covered Recipient Entity FUTURESEARCH TRIALS OF DALLAS LP | A PHASE 3, OPEN-LABEL, 1-YEAR STUDY OF THE SAFETY, TOLERABILITY, AND NEED FOR RE-TREATMENT WITH SAGE-217 IN ADULT SUBJECTS WITH MAJOR DEPRESSIVE DISORDER | No dispute reported | 06/30/2026 | 837506567 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $3,683.70 | 02/04/2021 | Non-covered Recipient Entity FUTURE SEARCH TRIALS OF DALLAS LP | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia | No dispute reported | 06/30/2026 | 806256567 |
| Principal investigator 1 | ITI, Inc. | $870.00 | 02/02/2021 | Non-covered Recipient Entity FUTURESEARCH TRIALS OF DALLAS LP | An Open-Label, MultiCenter Trial to Assess the Safety and Effectiveness of ITI-007 in Patients with Schizophrenia | No dispute reported | 06/30/2026 | 830288911 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $3,513.00 | 01/27/2021 | Non-covered Recipient Entity FUTURE SEARCH TRIALS OF DALLAS LP | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia | No dispute reported | 06/30/2026 | 806256563 |
| Principal investigator 1 | Janssen Research & Development, LLC | $10,847.00 | 01/21/2021 | Non-covered Recipient Entity FUTURESEARCH TRIALS OF DALLAS LP | An Open label Long term Extension Safety Study of Intranasal Esketamine in Treatment resistant Depression | No dispute reported | 06/30/2026 | 787664223 |
| Principal investigator 1 | Allergan, Inc. | $4,868.75 | 01/20/2021 | Non-covered Recipient Entity FUTURESEARCH TRIALS OF DALLAS | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ORAL UBROGEPANT IN THE TREATMENT OF MIGRAINE WHEN ADMINSTERED DURING THE PREMONITORY PHASE | No dispute reported | 06/30/2026 | 789018763 |
| Principal investigator 1 | ACADIA Pharmaceuticals Inc | $4,641.30 | 01/19/2021 | Non-covered Recipient Entity FUTURESEARCH TRIALS OF DALLAS | ACP-103-055 | No dispute reported | 06/30/2026 | 837697107 |
| Principal investigator 1 | Sage Therapeutics, Inc. | $4,558.32 | 01/19/2021 | Non-covered Recipient Entity FUTURESEARCH TRIALS OF DALLAS LP | A PHASE 3, OPEN-LABEL, 1-YEAR STUDY OF THE SAFETY, TOLERABILITY, AND NEED FOR RE-TREATMENT WITH SAGE-217 IN ADULT SUBJECTS WITH MAJOR DEPRESSIVE DISORDER | No dispute reported | 06/30/2026 | 837506251 |
| Principal investigator 1 | Biohaven Pharmaceuticals, Inc. | $778.05 | 01/14/2021 | Non-covered Recipient Entity FUTURESEARCH TRIALS OF DALLAS LP | A Phase 2/3 Randomized Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention | No dispute reported | 06/30/2026 | 851019825 |